Growth inhibition of human prostate cells in vitro by novel inhibitors of androgen synthesis

Cancer Research

Volumn 56, Issue 21, 1996, Pages 4956-4964

  Klus, Gregory T ^a   Nakamura, Junji ^a,c   Li, Ji Song ^a,d   Ling, Yang Zhi ^a   Son, Chong ^a   Kemppainen, Jon A ^b   Wilson, Elizabeth M ^b   Brodie, Angela M H ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c SNOW BRAND MILK PRODUCTS CO LTD   (Japan)

^d PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROSTANOLONE; FINASTERIDE; KETOCONAZOLE; PREGNANE DERIVATIVE; STEROID 17ALPHA MONOOXYGENASE; STEROID 5ALPHA REDUCTASE INHIBITOR; TESTOSTERONE; TETRAHYDROCORTISONE;

ANDROGEN SYNTHESIS; ARTICLE; CANCER HORMONE THERAPY; CANCER INHIBITION; GROWTH INHIBITION; HUMAN; HUMAN CELL; HUMAN TISSUE; INHIBITION KINETICS; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE HYPERTROPHY;

ANDROGEN ANTAGONISTS; ANDROGENS; CHOLESTENONE 5 ALPHA-REDUCTASE; DNA; HUMANS; MALE; OXIDOREDUCTASES; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS; STEROID 17-ALPHA-HYDROXYLASE; TESTOSTERONE; TUMOR CELLS, CULTURED;

EID: 0029950308     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (44)

1. Cheng, E., Lee, C , and Grayhack, J. Endocrinology of the prostate. In: H. Lepor and R. K. Lawson (eds.), Prostate Diseases, pp 57-73. Philadelphia W, B Saunders, 1993.
2. 21 steroid side chain cleavage: spectral and binding studies. J. Biol. Chem. 250: 6134-6139, 1981.
3. 17 20 lyase). cloning of human adrenal and testis cDNAs indicates the same gene is expressed in both tissues. Proc Natl. Acad Sci. USA, 84: 407-411, 1987.
4. Bruchovsky, N., and Wilson, J D The conversion of testosterone to 5α-androstan-17β-ol-3-one by rat prostate in vivo and in vitro J Biol. Chem , 243: 2012-2021, 1968
5. Saunders, F J Some aspects of relation of structure of steroids to their prostate-stimulating effects. In: E. P. Vollmer (ed.), Prostate and Related Tissues (National Cancer Institute Monograph No 12), pp. 139-159 Washington, DC U. S. Government Printing Office, 1963.
6. Dorfman, R. I , and Kincl, F. A. Relative potency of various steroids in anabolic-androgenic assay using the castrated rat. Endocrinology, 72, 259-266, 1963.
7. Petrow, V The dihydrotestosterone (DHT) hypothesis of prostate cancer and its therapeutic implications. Prostate, 9 343-361, 1986.
8. Zhou, Z-X , Wong, C-I , Sar, M., and Wilson, E. M. The androgen receptor, an overview. Recent Prog Horm. Res., 49: 249-274, 1994.
9. Chodak, G. W., Kranc, D. M., Puy, L. A., Takeda, H , Johnson, K., and Chang, C. Nuclear localization of androgen receptor in heterogeneous samples of normal, hyperplastic and neoplastic human prostate J. Urol., 147: 798-803, 1992.
10. Huggins, C., Stevens, R. E , and Hodges, C. V. Studies on prostatic cancer. II. The effects of castration on advanced carcinoma of the prostate gland. Arch. Surg , 43: 209-223, 1941.
11. Labrie, F., Dupont, A., Belanger, A., Lacoursiere, Y., Raynaud, J P., Husson, J. M., Gareau, J , Fazekas, A. T A., Sandow, J., Monfette, G., Girard, J G., Emond, J , and Houle, J G New approach in the treatment of prostate cancer: complete instead of partial withdrawal of androgens. Prostate, 4: 579-594, 1983.
12. Crawford, E. D , Eisenberger, M. A , McLeod, D. G , Spaulding, J. T., Benson, R , Dorr, F. A., Blumstein, B. A., Davis, M. A., and Goodman, P. J A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N. Engl J. Med., 321: 419-424, 1989
13. Crawford, E. D., Eisenberger, M., and McLeod, D. Treatment of newly diagnosed stage D2 prostate cancer with leuprolide and flutamide or leuprolide alone, phase III: prognostic significance of minimal disease J Urol., 147: 417A, 1992.
14. Denis, L. Role of maximal androgen blockade in advanced prostate cancer Prostate, 5 (Suppl ) 17-22, 1994.
15. Trachtenberg, J , and Pont, A. Ketoconazole therapy for advanced prostatic cancer Lancet, 2: 433-435, 1984
16. Williams, G , Kerle, D J , Doble, A , Dunlop, H., Smith, C , Allen, J., Yeo, T , and Bloom, S. R Objective responses to ketoconazole therapy in patients with relapsed progressive prostatic cancer Br J Urol , 58: 45-51, 1986.
17. Jubelirer, S. J , and Hogan, T. High dose ketoconazole for the treatment of hormone refractory metastatic prostate cancer: 16 cases and review of the literature. J Urol , 142: 89-91, 1989
18. Fleshner, N. E , and Trachtenberg, J Sequential androgen blockade, a biological study in the inhibition of prostatic growth. J Urol , 148 1928-1931, 1992.
19. Fleshner, N. E , and Trachtenberg, J. Treatment of advanced prostate cancer with the combination of finasteride plus flutamide early results. Eur Urol , 24 (Suppl. 2): 106-112, 1993.
20. Li, J-S., Li, Y , Son, C., and Brodie, A M. H Inhibition of androgen synthesis by 22-hydroximino-23,24-bisnor-4-cholen-3-one. Prostate, 26: 140-150, 1995.
21. Zhou, Z-X., Sar, M., Simental, J. A., Lane, M. V., and Wilson, E M. A ligand-dependent bipartite nuclear targeting signal in the human androgen receptor. J. Biol Chem. 269: 13115-13123, 1994
22. Horoszewicz, J S , Leong, S. S , Kawinski, E., Karr, J. P , Rosenthal, H , Chu, T M , Mirand, E A , and Murphy, G P LNCaP model of human prostatic carcinoma Cancer Res., 43, 1809-1818, 1983.
23. Neri, R., Peets, E , and Watnick, A. Anti-androgenicity of flutamide and its metabolite Sch 16423 Biochem. Soc. Trans., 7, 565-569, 1979.
24. Veldscholte, J., Ris-Stalpers, C , Kuiper, G. G J. M., Jenster, G , Berrevoets, C., Claassen, E., VanRooij, H. C. J , Trapman, J , Brinkmann, A O., and Mulder, E. A mutation in the ligand binding domain of the androgen receptor of human LNCaP cells affects steroid binding characteristics and response to anti-androgens Biochem. Biophys. Res Commun., 173: 534-540, 1990
25. Huggins, C , and Scott, W. W. Bilateral adrenalectomy in prostatic cancer. Ann. Surg , 122: 1031-1041, 1945.
26. Harper, M E , Pike, A., Peeling, W B , and Griffiths, K. Steroids of adrenal origin metabolized by human prostatic tissue both in vivo and in vitro. J Endocrinol., 60: 117-125, 1974.
27. Visakorpi, T., Hyytinen, E., Koivisto, P., Tanner, M., Keinanen, R , Palmberg, C., Palotie, A., Tammela, T , Isola, J., and Kalliomemi, O-P. In vivo amplification of the androgen receptor gene and progression of human prostate cancer. Nat. Genet., 9: 401-406, 1995.
28. Schuurmans, A. L. G., Bolt, J., Veldscholte, J., and Mulder, E. Stimulatory effects of antiandrogens on LNCaP human prostate tumor cell growth, EGF-receptor level and acid phosphatase secretion. J Steroid Biochem Mol Biol , 37: 849-853, 1990.
29. Wilding, G., Chen, M., and Gelmann, E. P. Aberrant response in vitro of hormone responsive prostate cancer cells to antiandrogens. Prostate, 14: 103-115, 1989.
30. Veldscholte, J., Berrevoets, C. A., Brinkmann, A. O., Grootegoed, J. A., and Mulder, E. Anti-androgens and mutated androgen receptor of LNCaP cells: differential effects on binding affinity, heat-shock protein interaction, and transcription activation. Biochemistry, 31, 2393-2399, 1992.
31. Simard, J., Veilleux, R., de Launoit, Y , Haagensen, D. E , and Labrie, F. Stimulation of apolipoprotein D secretion by steroids coincides with inhibition of cell proliferation in human LNCaP prostate cancer cells. Cancer Res., 51: 4336-4341, 1991.
32. Schuurmans, A. L. G., Bolt, J , Voorhorst, M M., Blankenstein, R. A., and Mulder, E. Regulation of growth and epidermal growth factor receptor levels of LNCaP prostate tumor cells by different steroids. Int. J Cancer, 42: 917-922, 1988.
33. Berns, E. M. J J., de Boer, W., and Mulder, E. Androgen-dependent growth regulation of and release of specific protein(s) by the androgen receptor containing human prostate tumor cell line LNCaP. Prostate, 9: 247-259, 1986.
34. Brolin, J., Skoog, L., and Ekman, P Immunohistochemistry and biochemistry in detection of androgen, progesterone and estrogen receptors in benign and malignant human prostatic tumors. Prostate, 20: 281-295, 1992
35. Castagnetta, L A., Miceli, M. D., Sorci, C. M. G., Pfeffer, U , Farruggio, R., Oliveri, G., Calabro, M , and Carruba, G. Growth of LNCaP human prostate cancer cells is stimulated by estradiol via its own receptor. Endocrinology, 136: 2309-2319, 1995.
36. Liang, T., Cascieri, M. A., Cheung, A. H., Reynolds, G. F , and Rasmusson, G. H. Species differences in prostatic steroid 5α-reductases of rat, dog, and human. Endocrinology, 117: 571-579, 1985.
37. Suzuki, H , Sato, N , Watabe, Y., Masai, M , Semo, S., and Shimazaki, J. Androgen receptor gene mutations in human prostate cancer. J. Steroid Biochem. Mol. Biol., 46: 759-765, 1993
38. Gaddipati, J. P., McLeod, D. G., Heidenberg, H B , Sesterhenn, I. A., Finger, M J , Moul, J. W., and Srivastava, S. Frequent detection of codon 877 mutation in the androgen receptor gene in advanced prostate cancers. Cancer Res , 54: 2861-2864, 1994.
39. Taplin, M-E., Bubley, G. J., Shuster, T. D., Frantz, M. E., Spooner, A. E , Ogata, G. K., Keer, H N., and Balk, S. P. Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer. N Engl. J. Med., 332: 1393-1398, 1995.
40. Sartor, O., Cooper, M., Weinberger, M., Headlee, D., Thibault, A , Tompkins, A., Steinberg, S , Figg, W. D., Linehan, W. M., and Myers, C. E. Surprising activity of flutamide withdrawal, when combined with aminoglutethimide, in treatment of "hormone-refractory" prostate cancer J Natl. Cancer Inst., 86: 222-227, 1994.
41. Scher, H. I., and Kelly, W. K. Flutamide withdrawal syndrome: its impact on clinical trials in hormone-refractory prostate cancer. J. Clin. Oncol., 11: 1566-1572, 1993.
42. Dupont, A., Gomez, J-L., Cusan, L., Koutsilieris, M., and Librie, F. Response to flutamide withdrawal in advanced prostate cancer in progression under combination therapy. J. Urol., 150 908-913, 1993.
43. Culig, Z., Hobisch, A., Cronauer, M. V., Cato, A. C. B , Hittmair, A., Radmayr, C., Eberle, J., Bartsch, G , and Klocker, H. Mutant androgen receptor detected in an advanced-stage prostatic carcinoma is activated by adrenal androgens and progesterone. Mol. Endocrinol., 7: 1541-1550, 1993.
44. Peterziel, H., Culig, Z , Stober, J., Hobisch, A., Radmayr, C., Bartsch, G., Klocker, H., and Cato, A. C B. Mutant androgen receptors in prostatic tumors distinguish between amino-acid sequence requirements for transactivation and ligand binding. Int. J. Cancer, 63: 544-550, 1995.